



#4

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 of 14

Complete if Known

Application Number	10/073,116
Filing Date	02/12/2002
First Named Inventor	BELLEAU
Group Art Unit	1624
Examiner Name	Not Yet Assigned McKee
Attorney Docket Number	IAF-1/2 C12

RECEIVED

JUL 2 2 2002

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
Jm	1	4,268,672		Vince	05/19/1981	
	2	5,827,727		Liotta et al.	10/027/1998	
	3	5,179,104		Chu et al.	01/12/1993	
	4	5,204,466		Liotta et al.	04/1993	
	5	5,210,085		Liotta et al.	05/1993	
	6	5,696,254		Mansour et al.	12/1997	
	7	5,684,010		Schinazi	11/04/1997	
	8	5,684,164		Belleau et al.	11/04/1997	
	9	5,700,937		Liotta et al.	12/23/1997	
	10	5,767,122		Chu et al.	06/16/1998	
	11	5,792,773		Chu et al.	08/11/1998	
	12	5,814,639		Liotta et al.	09/29/1998	
	13	5,830,898		Schinazi	11/3/1998	
	14	5,834,474		Schinazi	11/10/1998	
	15	5,852,027		Liotta et al.	12/22/1998	
	16	5,869,461		Cheng et al.	02/09/1999	
	17	5,914,331		Liotta et al.	06/22/1999	
	18	5,914,400		Liotta et al.	06/22/1999	
	19	5,684,010		Schinazi	11/04/1997	

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Num ber <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
Jm	20	WIPO	89/04662			06/1989		
	21	WIPO	90/12023			10/1990		
	22	WIPO	91/01326			02/1991		
	23	WIPO	92/10497			06/25/1992		
	24	WIPO	92/14729			09/03/1992		
	25	WIPO	92/18517			10/29/1992		
	26	WIPO	94/04154			03/03/1994		
	26A	EP	526253					
	26B	JP	0179118			11/1982		

Examiner  
Signature

Thomas A. Mullen


Date  
Considered

2/28/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2 of 14

Complete if Known

Application Number	10/073,116
Filing Date	02/12/2002
First Named Inventor	BELLEAU
Group Art Unit	1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	IAF-1/2 C12

RECEIVED  
JUL 22 2002

TECH CENTER 1600/2900

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
JH	27	4,000,137		Dvonch et al.	12/28/1976	
	28	4,041,037		Dvonch et al.	8/9/1977	
	29	4,336,381		Nagata et al.	6/22/1982	
	30	4,415,573		Ochi et al.	11/15/1983	
	31	4,960,773		Korbonits et al.	10/2/1990	
	32	5,041,449		Belleau et al.	8/20/1991	
	33	5,047,407		Belleau et al.	9/10/1991	
	34	5,151,426		Belleau et al.	9/29/1992	
	35	5,270,315		Belleau et al.	12/14/1993	
	36	5,276,151		Liotta et al.	1/4/1994	
JH	37	5,444,063		Schinazi	8/22/1995	
	38	5,466,806		Belleau et al.	11/14/1995	
	38A	5,234,913		Furman et al.	10/1993	
	38B	5,817,667		Chu et al.	11/15/1996	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
JH	40	EP	0 382 526			08/16/1990		
	41	EP	0 513 200			11/19/1992		
	42	EP	0 515 156			11/25/1992		
JH	43	JP	44-20392			09/2/1969		
	44	WO	92/14729			09/3/1992		

Examiner  
Signature

*[Handwritten Signature]*

Date  
Considered

*2/28/03*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for



Please type a plus sign (+) inside this box.

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>			
	Application Number	10/073,116		
	Filing Date	02/12/2002		
	First Named Inventor	BELLEAU		
	Group Art Unit	1624		
	Examiner Name	Not Yet Assigned		
4	of	14	Attorney Docket Number	IAF-1/2 C12

RECEIVED  
JUL 22 2002  
TECH CENTER 1600/2900

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ju	52	Declaration of Dr. Chung K. Chu, Opposition by Emory University, European Granted Patent Specification No. 337 713.	
ju	53	Chu et al., Tetrahedron Letter, Vol. 32, No. 31, pp. 3791-3794, 1991.	
	54	Kim et al., 1,3-Dioxolanylpurine Nucleosides (2R,4R) and (2R,4S) with Selective Anti-HIV-1 Activity in Human Lymphocytes, <i>Journal of Medical Chemistry</i> , Vol. 36, No. 1, pp. 30-37, 1993.	
	55	Kim et al., L-(2S,4S)- and L-α-(2S,4R)-Dioxolanyl Nucleosides as Potential Anti-HIV Agents: Asymmetric Synthesis and Structure-Activity Relationships, <i>Journal of Medical Chemistry</i> , Vol. 36, No. 5, March 5, 1993.	
	56	Kim et al., Potent Anti-HIV and Anti-HBV Activities of (-)-L-β-Dioxolane-C and (+)-L-β-Dioxolane-C and (+)-L-β-Dioxolane-T and Their Asymmetric Syntheses, <i>Tetrahedron Letters</i> , Vol. 33, No. 46, pp. 6899-69901, 1992.	
	57	Kim et al., Asymmetric Synthesis of 1,3-Dioxolane-Pyrimidine Nucleosides and Their Anti-HIV Activity, <i>Journal of Medical Chemistry</i> , Vol. 35, pp. 1987-1995, 1992.	
	58	Wilson et al., The Synthesis and Anti-HIV Activity of Pyrimidine Dioxolanyl Nucleosides, <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , Vol. 3, No. 2, pp. 169-174, 1993.	
	59	Table 1 - Activities and Toxicities of Selected 1,3-Dioxolane Nucleosides.	
	60	Allenmark, Chromatographic Enantioseparation: Methods and Applications, 1988.	
	61	Dr. Irving W. Wainer, A Practical Guide to the Selection and Use of HPLC Chiral Stationary Phases, presented by J.T. Baker, 1988.	
	62	Chiral Separations, Proceedings of the Chromatographic Society International Symposium on Chiral Separations, Ed. by Stevenson et al., September 3-4, 1987, published 1988.	

Examiner Signature		Date Considered	2/28/03
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

52 not public document



Please type plus sign (+) inside the box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

5 of 14

### Complete if Known

Application Number	10/073,116
Filing Date	02/12/2002
First Named Inventor	BELLEAU
Group Art Unit	1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	IAF-1/2 C12

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JP	63	Souter, Chromatographic Separations of Stereoisomers, 1985.	
	64	Herdewijn et al., Resolution of Aristeromycin Enantiomers, "Journal of Medical Chemistry, Vol. 28, pp. 1385-1386, 1985.	
	65	Secrist et al., Resolution of Racemic Carbocyclic Analogues of Purine Nucleosides through the Action of Adenosine Deaminase. Antiviral Activity of the Carbocyclic 2'-Deoxyguanosine Enantiomers, Journal of Medical Chemistry, Vol. 30, pp. 746-749, 1987.	
	66	DiMarco et al., High-performance liquid chromatographic determination of the isomeric purity of a series of dioxolane nucleoside analogues, Journal of Chromatography, Vol. 645 (1993), pp. 107-114.	
	67	Siddiqui et al., Antiviral Optically Pure dioxolane Purine Nucleosides Analogues, Bioorganic & Medicinal Chemistry Letters, Vol. 3, No. 8, pp. 1543-1546, 1993.	
	68	Fieser and Fieser, Organic Chemistry, 3 <sup>rd</sup> Edition, p. 290, 1956.	
	69	Translation of Römpps Chemie Lexikon volume 5, pp. 3455-3456, publication year 1987.	
	70	Carey and Sundberg, Advanced Organic Chemistry, 2 <sup>nd</sup> Edition, Part A: Structure and Mechanisms, pp. 73-75, 1984	
	71	Dixon and Webb, Enzymes, 2 <sup>nd</sup> Edition, p. 204, 1964.	
	72	Morrison, Asymmetric Synthesis, Volume 1, Analytical Methods, pp. 83-124, 1983.	
	73	Wainer and Drayer, Drug Stereochemistry: Analytical Methods and Pharmacology, Ch. 12, pp. 299-310, 1988.	

Examiner  
Signature

Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

6

of

14

### Complete if Known

Application Number	10/073,116
Filing Date	02/12/2002
First Named Inventor	BELLEAU
Group Art Unit	1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	IAF-1/2 C12

RECEIVED  
JUL 2 2 28 PM '03  
TECH CENTER 1600/2500

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>h</i>	74	Triangle Homepage, February 19, 1999; HIV and AIDS Drug Candidates, pp. 1-2 from Triangle website, February 19, 1999.	
<i>h</i>	75	BioChem Pharma Inc. Annual Report for 1997.	
	76	Sigma-Aldrich letter dated January 29, 1999.	
<i>u</i>	77	Frederiksen, <i>Specificity of Adenosine Deaminase Toward Adenosine and 2'-Deoxyadenosine Analogues</i> , <i>Archives of Biochemistry and Biophysics</i> , 113, 383-388, 1966.	
<i>h</i>	78	Pharmacia LKB Biotechnology Products Catalog 1988.	
	79	E-Mail from Ghromtech re the history of AGP columns to Danièle Ethier.	
	80	Curriculum Vitae for George R. Painter III, Ph.D., 10 pages.	
	81	George F. Painter's Declaration of January 1999 in the EP 0 337 713 Opposition.	
	82	Raymond F. Schinazi's Declaration of January 1999 in the EP 0 337 713 Opposition.	
	83	William H. Pirkle's Declaration of January 1999 in the EP 0 337 713 Opposition.	
	84	Anita T. Shortnacy-Fowler's Declaration of January 1999 in EP 0 337 713 Opposition.	
	85	Ernest L. Eliel's Declaration of January 1999 in the EP 0 337 713 Opposition.	

Examiner  
Signature


Date  
Considered

2/28/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

7 of 14

Complete if Known

Application Number	10/073,116
Filing Date	02/12/2002
First Named Inventor	BELLEAU
Group Art Unit	1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	IAF-1/2 C12

RECEIVED

JUL 2 2002

TECH CENTER 160012900

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	86	Correspondence dated January 6, 1999, from Yoshio Okamoto of Nagoya University to Sherry Knowles at Kilpatrick, Stock LLP regarding the commercial availability of Chiralcel OJ and Chiralpak AS and AD.	
RM	87	Norbeck et al., (+)-Dioxolane-T: A New 2',3'-Dideoxynucleoside Prototype with In Vitro Activity Against HIV, Tetrahedron Letters, Vol. 30, No. 46, pp. 6263-6266, 1989.	
	88	Belleau et al., Abstract T.C.O.1 Design and Activity of a Novel Class of Nucleoside Analogs Effective Against HIV-1," V International Conference on AIDS, The Scientific and Social Challenge, June 4-9, 1989, Montréal, Québec, Canada.	
	89	Michael D. Grim, Enzyphobia, Biocatalysis Works, Summer 1998.	
	90	Holý et al., Nucleic Acid Components and Their Analogues. Preparation and Properties of Some Nucleoside Hydroxyalkanephosphonates, Collection Czechoslov. Chem. Commun., Vol. 37, pp. 2066-2076, 1972.	
	91	M.W. Gray, Analysis of O <sup>2</sup> -Methylnucleoside 5'-Phosphates in Snake Venom Hydrolysates of RNA: Identification of O <sup>2</sup> -Methyl-5-Carboxymethyluridine as a Constituent of Yeast Transfer RNA, Canadian Journal of Biochemistry, Vol. 53, Number 7, pp. 735-746, July 1975.	
	92	Peter Pöchlauer, Syntheses of Homochiral Cyanohydrins in an Industrial Environment: Hydroxy Nitrile Lyases offer New Options, CHIMICA OGGI/chemistry today, Vol. 16, pp. 15-19, May 1998.	
	93	Lassota et al., Pyrimidine Homoribonucleosides: Synthesis, Solution Conformation, and Some Biological Properties, Z. Naturforsch. 42c., 589-598, 1987.	
	94	Rossomando, et al., 5'-Deoxy-5'-thioanalogs of Adenosine and Inosine 5'-Monophosphate: Studies with 5'-Nucleotidase and Alkaline Phosphatase, Archives of Biochemistry and Biophysics, Vol. 220, No. 1, January, pp. 71-78, 1983.	
	95	Holý, Nucleic Acid Components and Their Analogues. Synthesis of 6-Azaauridine 5'-Methanephosphonate and 6-Azaauridine 2'(3')-Methanephosphonate, Collection Czechoslov. Chem. Commun., Vol. 32, pp. 3713-3718, 1967.	
	96	Pless et al., Purine Nucleosides and Nucleotides Unequivocally in the Syn Conformation: Guanosine and 5'GMP with 8-tert-Butyl and 8-(c-Hydroxyisopropyl) Substituents, Z. Naturforsch. 33 c. 902-907 (1978).	


Examiner Signature	Date Considered 5/21/03
--------------------	-------------------------

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

8

of

14

## **Complete if Known**

Application Number	10/073,116
Filing Date	02/12/2002
First Named Inventor	BELLEAU
Group Art Unit	1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	IAF-1/2 C12

RECEIVED  
JUL 22 2002

TECH CENTER 1600/2900

## **OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JCU	97	Enzyme Nomenclature 1984, p. 282.	
	98	Bzowska et al., <i>Phosphorylation of Coformycin and 2'-Deoxycoformycin, and Substrate and Inhibitor Properties of the Nucleosides and Nucleotides in Several Enzyme Systems</i> , Z. Naturforsch. 40c, 710-714 (1985).	
	99	Mikhailopulo et al., <i>Substrate specificity of adenosine deaminase: the role of the substituents at the 2'- and 3'-carbons of adenine nucleosides, of their configuration and of the conformation of the furanose ring</i> , Biochemical Pharmacology, Vol. 30, No. 9., pp. 1001-1004, 1981.	
	100	Carson et al., <i>Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine</i> , Proceedings of the National Academy of Sciences of the United States of America, Biological Sciences, Volume 81, Number 7, pp. 2232-2236, April 1984.	
	101	Seela et al., <i>Synthesis of 1,7-Dideaza-2'-Deoxyadenosine and Related Pyrrolo[2,3-b] Puridine 2'-Deoxy-β-D-Ribonucleosides: Stereoselective Phase-Transfer Glycosylation Via the Nucleobase Anion</i> , Heterocycles, Vol. 29, No. 4, pp. 795-805, 1989.	
	102	Hasobe et al., <i>Effects of 9-(trans-2',trans-3'-Dihydroxycyclopent-4'enyl)-Adenine and -3-Deazaadenine on the Metabolism of S-Adenosylhomocysteine in Mouise L929 Cells</i> , Molecular Pharmacology, Vol. 33, No. 6, pp. 713-720, June 1988.	
	103	Cheikh et al., <i>Synthesis of Racemic 6'β-Hydroxyaristeromycin. A Hydroxycarbocyclic Analogue of Adenosine</i> , Organic Chemistry, Vol. 53, No. 5, pp. 929-936, March 1988.	
	104	Haertle et al., <i>Metabolism and Anti-human Immunodeficiency Virus-1 Activity of 2-Halo-2',3'-dideoxyadenosine Derivatives</i> , The Journal of Biological Chemistry, Vol. 263, No. 12, pp. 5870-5875, April 1988.	
	105	Davies et al., <i>Halogenated Pyrrolopyrimidine Analogues of Adenosine from Marine Organisms: Pharmacological Activities and Potent Inhibition of Adenosine Kinase</i> , Biochemical Pharmacology, Vol. 33, No. 3, pp. 347-355, February 1984.	
	106	Huang et al., <i>Effects of Cytotoxicity of 2-Chloro-2'-deoxyadenosine and 2-Bromo-2'-deoxyadenosine on Cell Growth, Clonogenicity, DNA Synthesis, and Cell Cycle Kinetics</i> , Cancer Research, Vol. 46, No. 5, pp. 2362-2368, May 1986.	
	107	Nachman et al., <i>Synthesis of Ara-doridosine, A New Arabinosyl Nucleoside Resistant to Adenosine Deaminase. X-Ray Structure Determination of 6-N,9(N)-Diacetyl-1(N)-methylisoguanine</i> , J. Chem. Soc., Perkins Transactions, pp. 1315-1320, 1985.	
	108	Schaumberg, et al., <i>2-Chloropentostatin, a New Inhibitor of Adenosine Deaminase</i> , J. Org. Chem., Vol. 50, pp. 1651-1656, 1985.	

Examiner  
Signature

Date

Considered


5/21/03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

9 of 14

### Complete if Known

Application Number	10/073,116
Filing Date	02/12/2002
First Named Inventor	BELLEAU
Group Art Unit	1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	IAF-1/2 C12

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JN	109	Hawkins et al., <i>Inhibitors of Adenosine Deaminase. Synthesis of Coformycin and 3'-Deoxycoformycin, Nucleosides &amp; Nucleotides</i> , Vol. 2, No. 5, pp. 479-494, 1983.	
	110	Stevenson and Leonard, <i>Defined Dimensional Alterations in Enzyme Substrates. lin-Naphthoadenine and lin-Naphthoadenosine</i> , <i>J. Organic Chemistry</i> , Vol. 49, pp. 2158-2164, 1984.	
	111	Thomas W. North, <i>Inhibition of Herpes Simplex Virus Replication by Purine Deoxyribonucleosides</i> , <i>Cancer Research</i> , Vol. 44, No. 4, pp. 1415-1419, 1984.	
	112	Plunkett et al., <i>Comparison of the Toxicity and Metabolism of 9-β-D-Arabinofuranosyl-2-Fluoroadenine and 9-β-D-Arabinofuranosyladenine in Human Lymphoblastoid Cells</i> , <i>Cancer Research</i> , Vol. 40, No. 7, pp. 2349-2355, July 1980.	
	113	Rossi and Lerner, <i>Specificity of Inhibition of Adenosine Deaminase by Trialcohols Derived from Nucleosides</i> , <i>Journal of Medicinal Chemistry</i> , Vol. 16, No. 5, pp. 457-460, 1973.	
	114	Tronchet and Tronchet, <i>Chimie et pharmacologie de l'apiose. IV Hydroxyméthyl-3-β-D-érythrofurannosyl-9-adenine: Synthèse, conformation en solution et essais biologiques préliminaires</i> , <i>Helvetica Chimica Acta</i> , Vol. 54, Fasc. 5, pp. 1466-1479, 1971.	
	115	Shuman et al., <i>Synthesis and Biological Activity of Certain 8-Mercaptopurine and 6-Mercaptopurymidine S-Nucleosides</i> , <i>Journal of Medicinal Chemistry</i> , pp. 653-659, 1969.	
	116	Cooney et al., <i>Initial Studies on the Cellular Pharmacology of 2',3'-Dideoxycytidine, an Inhibitor of HTLV-III Infectivity</i> , <i>Biochemical Pharmacology</i> , Vol. 35, No. 23, pp. 2065-2068, 1986.	
	117	Mahmoudian et al., <i>Enzymatic production of optically pure (2'R-cis)-2'-deoxy-3'-thiacytidine (3TC, Lamivudine): A potent anti-HIV agent</i> , <i>Enzyme Microb. Technol.</i> , Vol. 15, September, pp. 749-755, 1993.	
	118	Frick et al., <i>Transition State Stabilization by Deaminases: Rates of Nonenzymatic Hydrolysis of Adenosine and Cytidine</i> , <i>Bioorganic Chemistry</i> , Vol. 15, pp. 100-108, 1987.	
	119	Kati et al., <i>Contribution of a Single Hydroxyl Group to Transition-State Discrimination by Adenosine Deaminase: Evidence for an A-Entropy "Trap" Mechanism</i> , <i>Biochemistry</i> , Vol. 28, pp. 7919-7927, 1989.	

Examiner  
Signature


Date  
Considered

5/21/03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

10 of 14

Complete if Known

Application Number	10/073,116
Filing Date	02/12/2002
First Named Inventor	BELLEAU
Group Art Unit	1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	IAF-1/2 C12

RECEIVED

JUL 22 2002  
TECH CENTER 1600/2900

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
m	120	Frick et al., <i>Binding of Pyrimidin-2-one Ribonucleoside by Cytidine Deaminase as the Transition-State Analogue 3,4-Dihydrouridine and the Contribution of the 4-Hydroxyl Group to Its Binding Affinity</i> , <i>Biochemistry</i> , Vol. 28, pp. 9423-9430, 1989.	
	121	Wentworth et al., <i>Cytidine Deaminases (from Escherichia coli and Human Liver)</i> , <i>Methods in Enzymology</i> , Vol. LI, pp. 401-407, 1978.	
	122	J. Bryan Jones, <i>Illustrative Examples of Enzymes in Organic Synthesis</i> , Elsevier Science Publishing Co., pp. 3-14, 1986.	
C	123	Jin et al., <i>Unexpected Effects of Lewis Acids in the Synthesis of Optically Pure 2'-Deoxy-3'-oxacytidine Nucleoside Analogues</i> , <i>Tetrahedron: Asymmetry</i> , Vol. 4, No. 2, pp. 211-214, 1993.	
	124	<del>William Howard Pirkle's Curriculum Vitae.</del>	
ta	125	Krstulovic and Vende, <i>Improved Performance of the Second Generation <math>\alpha_1</math>-AGP Columns: Applications to the Routine Assay of Plasma Levels of Alfuzosin Hydrochloride</i> , <i>Chirality</i> , Vol. 1, pp. 243-245, 1989.	
	126	Lienne et al., <i>Direct enantiomeric separation of anticholinergic drugs derived from (+)-cyclohexyl(3-thienyl)glycolic acid on a novel <math>\alpha_1</math>-acid glycoprotein-bonded chiral stationary phase (Chiral-AGP)</i> , <i>Journal of Chromatography</i> , Vol. 467, pp. 406-413, 1989.	
	127	Thomas and Surber, <i>Preparative separation and analysis of the enantiomers of [<sup>3</sup>H]Abbott-69992, an HIV anti-infective nucleoside, by ligand-exchange high-performance liquid chromatography</i> , <i>Journal of Chromatography</i> , Vol. 536, pp. 265-270, 1991.	
	128	Montgomery et al., <i>The Use of Microparticulate Reversed-Phase Packing in High-Pressure Liquid Chromatography of Compounds of Biological Interest</i> , <i>Advances in Chromatography</i> , Vol. 15, pp. 169-195.	
	129	Montgomery et al., <i>The Use of Microparticulate Reversed-Phase Packing in High-Pressure Liquid Chromatography of Nucleosides, Chemistry and Biology of Nucleosides and Nucleotides</i> , pp. 37-53, Academic Press 1978.	
V	130	Däppen et al., <i>Applications and Limitations of Commercially Available Chiral Stationary Phases for High-Performance Liquid Chromatography</i> , <i>Journal of Chromatography</i> , Vol. 373, pp. 1-20, 1986.	
	131	<del>Ernest L. Eliel Curriculum Vitae.</del>	
gm	132	Temple et al., <i>Liquid chromatography assay of the calcium salt of citrovorum factor</i> , <i>Journal of Chromatography</i> , Vol. 140, No. 1, pp. 114-117, 1977.	

Examiner Signature

*Thomas M. G.*

Date Considered

5/21/03

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside the box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0661-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

11 of 14

### Complete if Known

Application Number	10/073,116
Filing Date	02/12/2002
First Named Inventor	BELLEAU
Group Art Unit	1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	IAF-1/2 C12

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TCU	133	Japanese Patent Patent Application No. 031324/1989, Notification of Reasons for Rejection, July 5, 1994. (Translation)	
TCU	134	Japanese Patent Application No. 31324/1990, Argument, January 31, 1995.	
	135	<del>Raymond Felix Schinazi, Curriculum Vitae.</del>	
	136	<del>Notice of Opposition by Emory University in European Granted Patent Specification No. 337 713 of July 1996.</del>	
	137	<del>Observations by BioChem Pharma Inc. in European Granted Patent Specification No. 337 713 on August 1997</del>	
	138	<del>Further Observations on December 24, 1998 by BioChem Pharma Inc. in European Granted Patent Specification No. 337 713</del>	
	139	<del>Observations on December 4, 1998 by Emory University in European Granted Patent Specification No. 337 713</del>	
	140	<del>BioChem Pharma's Reply of December 11, 1998 in European Granted Patent Specification No. 337 713</del>	
	141	<del>Emory University's Reply of January 1999 in European Granted Patent Specification No. 337 713</del>	
gm	142	Stereochemistry of Carbon Compounds, by E.L. Eliel (McGraw-Hill 1962) Section 4-4, , Section 5-5 & Section 15-1.	
gm	143	Tables of Resolving Agents, by S.H. Wilen (University of Notre Dame Press, 1972)	

Examiner  
Signature

*Thomas M. Kelly*

Date

Considered

5/21/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUL 2 2 2002

TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

12

of

14

Complete if Known

Application Number	10/073,116
Filing Date	02/12/2002
First Named Inventor	BELLEAU
Group Art Unit	1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	IAF-1/2 C12

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	144	<del>Emory's Timeline of 1,3-dioxolane enantiomer Production</del>	
	145	<del>Emory's Chart of Timeline</del>	
	146	<del>Collection of internal documents re BCH-203</del>	
	147	<del>Collection of internal documents re BCH-189</del>	
	148	<del>Emory's Commentary on BCH-189 internal documents</del>	
gcn	149	Belleau et al., Tetrahedron Lett., Vol. 33, 6949 (1992)	
	150	<del>Emory's Statement of Grounds for Appeal re Opposition to EP 0 337 713</del>	
gcn	151	The condensed Chemical Dictionary, ninth Ed. "Gesser G. Hawley, Van Nostrand, New York, 1977, page 16 and 252	
	152	Niedballa Ulrich and Vorbruggen, Helmut Nucl. Acid Chem. (1978), Volume 1, 431-3. Editor(s) Townsend, Leroy B. and Tipson, R. Stuart. Publisher: Wiley, New York, NY cited in 92: 198694 CA	
	153	Vorbrueggen, Helmut and Bennua, Baerbel, Chem. Ber. (1981), 114(4), 1279-86, cited in 95:43560 CA	
	154	Tsann Long Su; Bennua, Baerbel; Vorbrueggen, Helmut and Linder Hans Jeorg, Chem Ber. (1981), 114(4) 1269-78 cited in 95:25498	
	155	Vorbrueggen, Helmut; Hoefle and Gerhard, Chem. Ber. (1981), 114(4), 1256-68, cited in 95:25497 CA	
	156	Nucleoside syntheses. XXII. Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts, Vorbrueggen, Helmut; Krolkiewicz, Konrad; and Bennua, Baerbel, Chem Ber. (1981), 114(4), 1234-55, cited in 95:25496	
	157	S.L. Doong et al., Proc Natl. Acad. Sci. 88, 1991, 8495	

Examiner  
Signature

*Thomas Muller*

Date  
Considered

5/21/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED  
JUL 12 2002

TECH CENTER 1600/2900



Please type a plus sign (+) inside the box

+

PTO/SB/48A (08-00)

Approved for use through 10/31/2002. OMB 0451-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

13

of

14

Complete if Known

Application Number 10/073,116

Filing Date 02/12/2002

First Named Inventor BELLEAU

Group Art Unit 1624

Examiner Name Not Yet Assigned

Attorney Docket Number IAF-1/2 C12

RECEIVED

JUL 2 2 42

TECH CENTER 1600/2900

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RM	158	Wang, Wei et al. Tet. Let. 35, 1994, p4739-4742	
	159	Norbeck et al., Chemical Abstracts, vol. 113(3):24406q (1990).	
	160	Mitsuya et al., "3'-Azido 3'-Deoxythymidine (BWA509U): An Antiviral Agent that Inhibits the Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy--Associated Virus In Vitro", <i>Proc. Natl. Acad. Sci., U.S.A.</i> 82, pp. 7096-7100 (1985).	
	161	Mitsuya et al., "Inhibition of the In Vitro Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy--Associated Virus (HTLV-III/LAV) by 2', 3'-Dideoxynucleosides", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 83, pp. 1911-1915 (1986).	
	162	Balzarini et al., "Potent and Selective Anti-HT-LV-III/LAV Activity of 2',3'-Dideoxycytidine, the 2',3'-Unsaturated Derivative of 2',3'-Dideoxycytidine", <i>Biochemical and Biophysical Research Communications</i> , 140 (2), pp. 735-742 (1986).	
	163	Baba et al., "Both 2',3'-Dideoxythymidine and its 2',3'-Unsaturated Derivative (2',3'-Dideoxythymidine) are Potent and Selective Inhibitors of Human Immunodeficiency Virus Replication in Vitro", <i>Biochemical and Biophysical Research Communications</i> , 142(1), pp. 128-134 (1987).	
	164	Lin et al., "Synthesis and Antiviral Activity of Various 3'-Azido, 3'-Amino, 2',3'-Unsaturated, and 2',3'-Dideoxy Analogues of Pyrimidine Deoxyribonucleosides Against Retroviruses", <i>J. Med. Chem.</i> , 30, pp. 440-444 (1987).	
	165	Herdewijn et al., "3'-Substituted 2',3'-Dideoxynucleoside Analogues as Potential Anti-HIV (HTLV-III/LAV) Agents", <i>J. Med. Chem.</i> , 30, pp. 1270-1278 (1987).	
	166	Hallonquist et al., "Studies on Reactions Relating to Carbohydrates and Polysaccharides", <i>Canadian Journal of Research</i> , 7, pp. 129-136 (1933).	
	167	Corey et al., "Useful Procedures for the Oxidation of Alcohols Involving Pyridinium Dichromate in Aprotic Media", <i>Tetrahedron Letters</i> , 5, pp. 399-402 (1979).	
	168	Barton et al., "Transformations of Penicillin. Part III. A New Route to 2,2-Dimethyl-6a-Phenylacetamidopenam- $\alpha$ -Ols-Oxide and its Esters; O-NitroBenzoate as a Protecting Group for Alcohols and Phenols", <i>J. Chem. Soc. Perkin I</i> , pp. 599-603 (1973).	
	169	Wise et al., "Replacement of the 2-and 4-Oxo Groups of Uridine by a Seleno Group", <i>Nucleic Acid Chemistry</i> , pp. 413-419 (1978).	

Examiner  
Signature

Date  
Considered

5/21/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box

PTO/S&T/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0041  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

14

of

14

### Complete if Known

Application Number 10/073,116

Filing Date 02/12/2002

First Named Inventor BELLEAU

Group Art Unit 1624

Examiner Name *Mr. K. K. K.*

Attorney Docket Number IAF-1/2 C12

RECEIVED  
JUL 2 2002

TECH CENTER 1600/2900

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>Pen</i>	170	Ueda et al., "Synthesis and Optical Properties of 2,3-Dideoxy-D-Erythro-Hex-2-Enopyranosyl Nucleosides (Nucleosides and Nucleotides, LXII)", <i>Chem. Pharm. Bull.</i> , 33(9), pp. 3689-3695 (1985).	
	171	Gosselin et al., "Systematic Synthesis and Biological Evaluation of $\alpha$ - and $\beta$ -D-Lyxofuranosyl Nucleosides of the Five Naturally occurring Nucleic Acid Bases", <i>J. Med. Chem.</i> , 30, pp. 982-991 (1987).	
	172	Baum et al., Chemical and Engineering News, vol. 67(26), 1989, pp. 7-15.	
	173	Mark K. Sachs, Arch. Intern. Med. vol. 152, 1992, pp. 485-501.	
	174	P. Herdewijn and E. De Clercq, "Dideoxynucleoside Analogues As Inhibitors of HIV Replication", <i>Design of anti-Aids Drugs</i> , E. De Clercq, ed (Elsevier, 1990).	
	175	Belleau et al., "Design and Activity of a Novel Class of Nucleoside Analogs Effective Against HIV-1", Fifth International Conference on AIDS, Montreal, Canada, Abstract T.C.O. 1(1989).	
	176	Carlisle et al., "Cellular Pharmacology of the Anti-HIV Agent BCH-189 (2'-Deoxy-3'-thiacytidine) In Human Peripheral Blood Mononuclear Cells (PBMC)", <i>American Association for Cancer Research Proceedings</i> , 31, abstract 2435, (1990).	
	177	Huryn et al., "Synthesis of Iso-ddA, Member Of A Novel Class of Anti-HIV Agents-Dioxolane-T, A New 2',3'-Dideoxynucleoside Prototype With In Vitro Activity Against HIV", <i>Chemtracts-Organic Chemistry</i> , 3, pp. 249-251 (1990).	
	178	Norbeck et al., "(+)-Dioxolant-T", <i>Tetrahedron Lett.</i> , 30, pp. 6263-6266 (1989).	
	179	Wainberg et al., "Anti-HIV Activity, toxicity and Pharmacokinetics of Totally Novel Nucleoside Analogs", Fifth International Conference on AIDS, Montreal, Canada, Abstract M.C.P. 63, p. 552 (1989).	
	180	Wainberg et al., "Characterization of AZT-Resistant isolates of HIV-1: Susceptibility To Deoxythiacytidine and Other Nucleosides", Sixth International Conference on AIDS, San Francisco, CA., vol. 3, Abstract S.B.87, p. 117, (1990).	

Examiner  
Signature

Date  
Considered

5/21/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.